未知股票 PTN 深 沪
等待开盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 2814.88万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palatin Technologies Begins Trading on OTCQB Market
Palatin Technologies ( ($PTNTD) ) has provided an update. Effective September 1...
09-10 20:58
St Barbara Acquires Strategic Stake in Geopacific Resources
An update from Kin Mining NL ( ($AU:PTN) ) is now available. St Barbara Ltd, a ...
08-22 06:38
Patronus Resources Secures Shareholder Approval for Selective Buy-Back
An announcement from Kin Mining NL ( ($AU:PTN) ) is now available. Patronus Res...
08-20 13:27
93亿！礼来押注AI+蛋白质动力学Biotech
（来源：动脉新医药） 8月14日，Superluminal Medicines宣布与礼来合作，利用其专有平台发现和优化与心脏代谢疾病和肥胖相关的未公开GPCR靶...
08-15 17:54
Palatin Announces 1-for-50 Reverse Stock Split
PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50. Th...
08-09 04:00
Patronus Resources Unveils Investment Opportunity with Strong Resource Base
Kin Mining NL ( ($AU:PTN) ) just unveiled an announcement. Patronus Resources L...
08-04 06:58
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favorable safety profile.
07-23 19:30
Palatin Technologies Faces NYSE Delisting Proceedings
The latest update is out from Palatin Technologies ( ($PTNT) ). On July 7, 2025...
07-09 21:30
用户无感知，信号“零中断” 省公司安播中心完成连云港新机房自主搬迁
编者按： 一次大规模机房搬迁，难免出现信号中断、业务暂停和用户报修。然而，省公司安播中心凭借深厚的技术积累和团队间的紧密协作，在落实“降本增效”要求的同时，让信...
07-03 17:46
Purple Biotech Presents New Preclinical Data On CAPTN-3 Tri-Specific Antibody Platform At EACR 2025
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced
06-23 19:06
